Dr. Welling on Incorporating Immunotherapy Into HCC Paradigm

Theodore H. Welling, MD
Published: Saturday, Sep 16, 2017



Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses how immunotherapy agents will eventually fit into the paradigm of hepatocellular carcinoma. (HCC).

How immunotherapy fits is going to be a major area of research, Welling explains. There are a lot of caveats and permutations, which makes the therapy potentially exciting, he adds.

Additionally, optimally incorporating immunotherapy will include combining and further characterizing which patients are most likely to respond to immuno-oncology therapy. There are other agents that block or accelerate other pathways of the immune response, Welling says. Therefore, combining this type of therapy with other agents that block either other co-inhibitory pathways or combining with other agents that maybe accelerate other pathways of the immune response is another area of research. 

Brought to you in part by Eisai


Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses how immunotherapy agents will eventually fit into the paradigm of hepatocellular carcinoma. (HCC).

How immunotherapy fits is going to be a major area of research, Welling explains. There are a lot of caveats and permutations, which makes the therapy potentially exciting, he adds.

Additionally, optimally incorporating immunotherapy will include combining and further characterizing which patients are most likely to respond to immuno-oncology therapy. There are other agents that block or accelerate other pathways of the immune response, Welling says. Therefore, combining this type of therapy with other agents that block either other co-inhibitory pathways or combining with other agents that maybe accelerate other pathways of the immune response is another area of research. 

Brought to you in part by Eisai



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x